Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432F. Wang, Rui‐Hua Xu, Xiaoli Wei et al.|Annals of Oncology|2019Cited by 475
Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02)Feng‐Hua Wang, Rui‐Hua Xu, Xiaoli Wei et al.|Journal of Clinical Oncology|2021Cited by 350
Research progress in polylactic acid processing for 3D printingXiyue Wang, Yang Liu, Lijie Huang et al.|Journal of Manufacturing Processes|2024Cited by 110
Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trialTao Jiang, Shengxiang Ren, Jianying Zhou et al.|Signal Transduction and Targeted Therapy|2021Cited by 94
Anaplastic Lymphoma Kinase Is Required for Neurogenesis in the Developing Central Nervous System of ZebrafishSheng Yao, Christoph Winkler|PLoS ONE|2013Cited by 79